How a 100-Year-Old Formula Could Stop Lifesaving Cancer Therapy How a 100-Year-Old Formula Could Stop Lifesaving Cancer Therapy

Potentially lifesaving cancer therapy may be stopped because of QTc findings. But often that measurement is based on a century-old formula that is being questioned.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Related Links:

AbstractPurposeThe oldest old, described as those aged 85 and older, is a growing cancer population. There are limited studies evaluating the symptoms of the oldest old cancer patient population. Our study aimed to evaluate symptom frequency and clinical symptom change as assessed by the Edmonton Symptom Assessment System (ESAS) of the oldest old ( ≥ 85) compared to older adult (65–84) and general adult (18–64) outpatient cancer patients on initial consult and follow-up visit.MethodsRetrospective review of a total of 441 patients, 200 randomly sampled patients in the general and older adult group and ...
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
Dr Tony Mok of Hong Kong University reviews key studies on non-small cell lung cancer therapies, presented at the 2019 annual meeting of the European Society for Medical Oncology (ESMO).Medscape
Source: Medscape Today Headlines - Category: Consumer Health News Tags: None ReCAP Source Type: news
Publication date: Available online 16 October 2019Source: Materials Science and Engineering: CAuthor(s): Ganesan Raja, Shijie Cao, Deok-Ho Kim, Tae-Jin KimAbstractTitanium dioxide (TiO2) nanoparticles (NPs), first developed in the 1990s, have been applied in numerous biomedical fields such as tissue engineering and therapeutic drug development. In recent years, TiO2-based drug delivery systems have demonstrated the ability to decrease the risk of tumorigenesis and improve cancer therapy. There is increasing research on the origin and effects of pristine and doped TiO2-based nanotherapeutic drugs. However, the detailed mole...
Source: Materials Science and Engineering: C - Category: Materials Science Source Type: research
Tumor-treating fields (TTFields) is a non-invasive physical modality of cancer therapy that applies low-intensity, intermediate frequency, alternating electric fields to a tumor. Interference with mitosis was the first mechanism describing the effects of TTFields on cancer cells, however, TTFields was shown to not only reduce the rejoining of radiation-induced DNA double-strand breaks (DSBs), but to also induce DNA DSBs. The mechanism(s) by which TTFields generates DNA DSBs is related to the generation of replication stress including reduced expression of the DNA replication complex genes MCM6 and MCM10 and the Fanconi's Anemia pathway genes.
Source: Translational Research - Category: Research Authors: Source Type: research
In this study, we compared differences in gene expression in parental and CHD4-deficient cells by next-generation sequencing and Ingenuity Pathway Analysis.Key findingsWe found that β1 integrin is a downstream target gene of CHD4, which could be transcriptionally regulated by CHD4 in TNBC cells. Consistent with in vitro data, immunohistochemistry revealed that co-expression of β1 integrin and CHD4 was significantly associated with metastatic state, recurrence, and survival status in TNBC patients. It also showed a positive correlation between β1 integrin and CHD4 in vivo.SignificanceThis is the first study t...
Source: Life Sciences - Category: Biology Source Type: research
No abstract available
Source: Oncology Times - Category: Cancer & Oncology Tags: News Source Type: research
Publication date: Available online 18 October 2019Source: Acta Pharmaceutica Sinica BAuthor(s): Zongru Jiang, Li Wang, Xuesong Liu, Cheng Chen, Beilei Wang, Wenliang Wang, Chen Hu, Kailin Yu, Ziping Qi, Qingwang Liu, Aoli Wang, Jing Liu, Guangchen Hong, Wenchao Wang, Qingsong LiuAbstractAngiogenesis is an essential process in tumor growth, invasion and metastasis. VEGF receptor 2 (VEGFR2) inhibitors targeting tumor angiogenic pathway have been widely used in the clinical cancer treatment. However, most of currently used VEGFR2 kinase inhibitors are multi-target inhibitors which might result in target-associated side effect...
Source: Acta Pharmaceutica Sinica B - Category: Cancer & Oncology Source Type: research
Authors: Gupta S, Pathak Y, Gupta MK, Vyas SP Abstract Ovarian cancer is the second most common gynaecological malignancy. It usually occurs in women older than 50 years, and because 75% of cases are diagnosed at stage III or IV it is associated with poor diagnosis. Despite the chemosensitivity of intraperitoneal chemotherapy, the majority of patients is relapsed and eventually dies. In addition to the challenge of early detection, its treatment presents several challenges like the route of administration, resistance to therapy with recurrence and specific targeting of cancer to reduce cytotoxicity and side ...
Source: Artificial Cells, Nanomedicine and Biotechnology - Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research
In this study, we showed that FGF2 is significantly increased in ovarian tumors, and is negatively associated with the overall survival of ovarian cancer by database analysis. A short peptide obtained from a heptapeptide phage display library suppressed FGF2-induced proliferation, migration, and invasion of the p53-null epithelial ovarian cancer (EOC) cells. Further investigations revealed that the short peptide antagonized the effects of FGF2 on G0/G1 to S cell phase promotion, cyclin D1 expression, and MAPK and Akt signaling activation, which might contribute to the mechanism underlying the inhibitory effects of the shor...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Preclinical Reports Source Type: research
Publication date: Available online 17 October 2019Source: Life SciencesAuthor(s): Keywan Mortezaee, Yaiza Potes, Hanifeh Mirtavoos-Mahyari, Elahe Motevaseli, Dheyauldeen Shabeeb, Ahmed Eleojo Musa, Masoud Najafi, Bagher FarhoodAbstractCancer is a disease of high complexity. Resistance to therapy is a major challenge in cancer targeted therapies. Overcoming this resistance requires a deep knowledge of the cellular interactions within tumor. Natural killer (NK) cells and cytotoxic T lymphocytes (CTLs) are the main anti-cancer immune cells, while T regulatory cells (Tregs) and cancer associated fibroblasts (CAFs) facilitate i...
Source: Life Sciences - Category: Biology Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Hematology